Videos

Sasirekha Ramani, PhD on creating a broad-spectrum antiviral that could be effective in various clinical settings, especially given the emergence of new and more dominant strains.

Robert Allen, PhD, discusses how Pemgarda’s stability in targeting the spike protein's receptor-binding domain offers crucial protection, including immunocompromised individuals.

Gregory Fox, PhD outlines the trial's challenges, the impact of combining results with the TB Champ trial, and the role of collaboration in strengthening research outcomes.

This is the second in a series looking at the intersection of government and public health. In this segment, Contagion Editor-in-Chief Jason Gallagher, FCCP, FIDP, FIDSA, BCPS, discusses the WHO pullout, and the pauses on federal communication and research grants.

Alejandro Krolewiecki, MD discusses the path to regulatory approval, collaboration with global health organizations, and the role of partnerships in scaling up the new treatment for neglected tropical diseases.

GAFFI is addressing fungal diagnostic gaps by raising awareness, implementing models, and advocating for resource shifts, despite challenges in funding, infrastructure, and political support.

Alejandro Krolewiecki, MD, discussed testing a combination of albendazole and ivermectin to improve treatments for neglected tropical diseases.

Research into new antifungal treatments, including drugs in phase two and three trials, offers hope for patients who do not respond to current therapies.

Wendy Dann has MS and describes her experience with a copay assistance program that provides insurers with additional revenue, but does not go towards her deductible.

The impact of the "95-95 by 2025" campaign and successes in countries like Uzbekistan and Guatemala, where action to improve diagnostic tools has addressed fungal infection challenges.

George Thompson, MD, explains a rise in Valley fever cases in CA, with concerns about increased virulence, ICU admissions, and the impact of droughts and wildfires on fungal spread.

David W Denning, FRCP, FRCPath, FMedSci, outlines the "95-95 by 2025" initiative to diagnose and treat 95% of serious fungal infections globally by 2025, focused on improving access in underserved regions.

Sasirekha Ramani, PhD, discusses the potential of 2′FL as a treatment for norovirus and what more research could reveal.

Caryn Fenner and Petro Terblanche outline Afrigen's clinical trial plans, local partnerships, and vaccine pipeline.

In the second interview segment with George Thompson, MD, he provides feedback on patient profiles and prescribing practices for the antifungal.

Caryn Fenner and Petro Terblanche explain how CEPI’s $6.2 million grant will advance Afrigen’s mRNA vaccine for Rift Valley fever through preclinical and Phase I trials in Africa.

The federal government is working on measures to mitigate the potential impact including looking at vaccines, therapies, and other strategies. Robert Hopkins, Jr, MD, medical director, National Foundation for Infectious Diseases (NFID), provides some insights on our preparation now and lessons learned from the pandemic.

George Thompson, MD, offers some insights on 2 studies looking at these antifungals in patients with candidemia and invasive candidiasis.

NACCHO’s CEO Lori Tremmel Freeman discusses efforts and emphasizes the need for federal support and coordination.

CEO Lori Tremmel Freeman discusses NACCHO's capacity-building programs and strategies to strengthen local health departments in addressing evolving public health threats.

Robert H. Hopkins, Jr, MD, medical director, National Foundation for Infectious Diseases (NFID) provides an update on incidence rates and virus patterns across different regions of the US.

There are high infection rates in this population, but limited opportunities to bring about awareness and education. However, a newer program sponsored by ViiV Healthcare looks to engage these women and bring about a better understanding behind transmission and care.

In the second part of our conversation, Abdulwhab Shremo Msdi, PharmD, discusses using this methodology.

Abdulwhab Shremo Msdi, PharmD, offers insights on its complexities, why institutions have been slower to include this dosing technique, and why clinicians need to consider this approach.

Larry Sutton, MD, PhD, discussed how oxygen affects C. difficile and provides anti-inflammatory effects in the gut, with potential applications for gastrointestinal diseases.

CEO Larry Sutton, MD, PhD, discusses SIDIPREV, a novel oxygen-based therapy aimed at preventing C difficile infections.

Rising temperatures and changing humidity are undermining natural pest control, putting North American forests at risk.

Exploring the challenges and strategies for combating MDR Pseudomonas aeruginosa infections, as discussed with Jason Pogue, PharmD, BCPS, BCIDP

This week the panel weighs in on monoclonal antibodies in this patient population as well as important overall takeaways about COVID-19 therapies.

Jason M Pogue, PharmD, BCPS, BCIDP discussed ceftolozane tazobactam’s effectiveness over ceftazidime avibactam, particularly in pneumonia patients, where it reduced the likelihood of recurrent infections.